PHARMANUTRA S.P.A.: THE DISTRIBUTION OF IRON-BASED DIETARY SUPPLEMENTS KICKS OFF IN MEXICO
Partner SMS Pharma will market the three products in the SiderAL® line under the trade name Sucrosom®, which is based on our ground-breaking, patented Sucrosomial® Technology.
Last month, in
The products -Sucrosom® F15 30 capsules (SiderAL® Forte 15mg), Sucrosom® Fol 20mg 20 sticks (SiderAL® Folico 20mg) and Sucrosom® Gotas (SiderAL® P Drops)- are those of the line of iron-based dietary supplements on the Italian and international market under the SiderAL® brand name and made on the basis of Sucrosomial® Technology, the innovative delivery system, designed and patented by PharmaNutra, which improves absorption and tolerability of microelements, macroelements and phytoextracts essential for the human body. They will be marketed in the main urban areas of
PharmaNutra's presence in the Central American region includes, along with
Investor Relations PharmaNutra
050 7846500
[email protected]
Emanuel Richelmy, PharmaNutra
+39 391 7310645
[email protected]
Cristina Tronconi
+39 346 0477901
[email protected]
+39 347 9834881
[email protected]
Logo - https://mma.prnewswire.com/media/2441716/PharmaNutra_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmanutra-spa-the-distribution-of-iron-based-dietary-supplements-kicks-off-in-mexico-302183026.html
SOURCE PharmaNutra S.p.A.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026
- Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting
- Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share